-- CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation

-- Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies

The decision is intended to assure current and future generic manufacturers that they may manufacture and sell generic versions of SIRTURO® without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.

Stop TB Partnership and Johnson & Johnson, with support from USAID and the Global Fund, announce price reduction for bedaquiline for treatment of drug-resistant TB in low- and middle-income countries.

In advance of the 50th Union World Conference on Lung Health, Johnson & Johnson announced the expansion of its TB program in India. Through a series of new collaborations with several multilateral and non-governmental organizations, as well as the Government of India, the company aims to help support the country's efforts to end TB by 2025, as outlined in its National Strategic Plan for TB Elimination.

Johnson & Johnson announced it has committed to ensuring more than $500 million dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and TB by 2030.

J&J’s goal is to save an estimated 1.8 million lives and prevent 12 million new TB infections.

Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria

New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments